PRRT2 and plasma cell myeloma: Bryostatin-1, a protein kinase C (PKC) inhibitor and antagonist of the cyclin B-CDK1 complex, has been explored in the clinic for the treatment of multiple myeloma [48], relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia [49].